<p>The whole exome sequencing showed that HERC5 deletion and under-expression associates with shorter: time to tumor recurrence, progression-free, and overall survival in hepatocellular carcinoma (HCC) in two independent studies (p1=0.004, HR1=1.80; p2=0.018, HR2=3.31) totaling 286 HCC patients. Matched primary and recurrent tumors indicated a clonal selection advantage in somatic single nucleotide and copy number variants (CNVs) in recurrent compared to primary tumors of Chinese HCC patients with Wnt signaling most activated.</p>

Post-Liver Transplant Recurrent Human Hepatocellular Carcinoma Study    (RHCCS)

1 selected publication including "HERC5 is a prognostic biomarker for post-liver transplant recurrent hu..." (28 citations)

Post-Liver Transplant Recurrent Human Hepatocellular Carcinoma Study (RHCCS)

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma